Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Observational Study to IDEntify Patients With Advanced/Metastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK&ROS)

Inclusion Criteria:

For ALK Incidence substudy

• Patients with Advanced or metastatic non-small cell lung cancer
• Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement
• Age > 18 years For ALK treatment substudy (retrospective and prospective)
• Age > 18 years
• Confirmed anaplastic lymphoma kinase (ALK)-positive tumour
• Patients treated with crizotinib under routine clinical practice
• Patients with a minimum data registered at the medical history
• For the patients that will be recruited prospectively: Patients must have a signed informed consent document.

For the ROS1 treatment sub-study (retrospective only):

• Age > 18 years
• Confirmation of NSCLC with ROS1-positive translocation
• Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.
• Patients should have a predetermined minimum amount of data recorded in their medical records.

Exclusion Criteria:

• Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the sub-study for which they are included.